Literature DB >> 21429292

Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models.

Sang Kyun Lim1, Sheila R Alcantara Llaguno, Renée M McKay, Luis F Parada.   

Abstract

Gliomas are the most frequently occurring primary malignancies in the central nervous system, and glioblastoma multiforme (GBM) is the most common and most aggressive of these tumors. Despite vigorous basic and clinical studies over past decades, the median survival of patients with this disease remains at about one year. Recent studies have suggested that GBMs contain a subpopulation of tumor cells that displays stem cell characteristics and could therefore be responsible for in vivo tumor growth. We will summarize the major oncogenic pathways abnormally regulated in gliomas, and review the recent findings from mouse models that our laboratory as well as others have developed for the study of GBM. The concept of cancer stem cells in GBM and their potential therapeutic importance will also be discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21429292      PMCID: PMC3719878          DOI: 10.5483/BMBRep.2011.44.3.158

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  58 in total

1.  Neurogenesis in the adult rat: electron microscopic analysis of light radioautographs.

Authors:  M S Kaplan; J W Hinds
Journal:  Science       Date:  1977-09-09       Impact factor: 47.728

2.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

Authors:  E C Holland; J Celestino; C Dai; L Schaefer; R E Sawaya; G N Fuller
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

Review 3.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

4.  Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

Authors:  D H Gutmann; S A Rasmussen; P Wolkenstein; M M MacCollin; A Guha; P D Inskip; K N North; M Poyhonen; P H Birch; J M Friedman
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

5.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

Authors:  Robert M Bachoo; Elizabeth A Maher; Keith L Ligon; Norman E Sharpless; Suzanne S Chan; Mingjian James You; Yi Tang; Jessica DeFrances; Elizabeth Stover; Ralph Weissleder; David H Rowitch; David N Louis; Ronald A DePinho
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

Review 6.  The molecular and genetic basis of neurological tumours.

Authors:  Yuan Zhu; Luis F Parada
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

7.  Identification of a cancer stem cell in human brain tumors.

Authors:  Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

8.  Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation.

Authors:  Rita U Lukacs; Sanaz Memarzadeh; Hong Wu; Owen N Witte
Journal:  Cell Stem Cell       Date:  2010-12-03       Impact factor: 24.633

9.  Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression.

Authors:  A T Collins; F K Habib; N J Maitland; D E Neal
Journal:  J Cell Sci       Date:  2001-11       Impact factor: 5.285

10.  Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis.

Authors:  Akira Tsujimura; Yasuhiro Koikawa; Sarah Salm; Tetsuya Takao; Sandra Coetzee; David Moscatelli; Ellen Shapiro; Herbert Lepor; Tung-Tien Sun; E Lynette Wilson
Journal:  J Cell Biol       Date:  2002-06-24       Impact factor: 10.539

View more
  31 in total

1.  High copy number of mitochondrial DNA (mtDNA) predicts good prognosis in glioma patients.

Authors:  Yanfang Zhang; Yiping Qu; Ke Gao; Qi Yang; Bingyin Shi; Peng Hou; Meiju Ji
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Inactivation of Wild-Type p53 by Asparagine Endopeptidase in Glioblastoma: An Opportunity to Target the "Undruggable".

Authors:  James J Manfredi
Journal:  J Natl Cancer Inst       Date:  2020-04-01       Impact factor: 13.506

3.  Extracellular Matrix Glycoprotein-Derived Synthetic Peptides Differentially Modulate Glioma and Sarcoma Cell Migration.

Authors:  Nicole Brösicke; Muhammad Sallouh; Lisa-Marie Prior; Albert Job; Ralf Weberskirch; Andreas Faissner
Journal:  Cell Mol Neurobiol       Date:  2015-03-18       Impact factor: 5.046

4.  Gene expression profiling analysis reveals that DLG3 is down-regulated in glioblastoma.

Authors:  Zhongyu Liu; Yulong Niu; Mengyu Xie; Youquan Bu; Zhiqiang Yao; Chunfang Gao
Journal:  J Neurooncol       Date:  2014-01-01       Impact factor: 4.130

5.  Aggravated DNA damage as a basis for enhanced glioma cell killing by MJ-66 in combination with minocycline.

Authors:  Mann-Jen Hour; Wei-Ting Liu; I-Chen Lu; Sheng-Chu Kuo; Po-Wu Gean
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 6.  Emerging insights into the molecular and cellular basis of glioblastoma.

Authors:  Gavin P Dunn; Mikael L Rinne; Jill Wykosky; Giannicola Genovese; Steven N Quayle; Ian F Dunn; Pankaj K Agarwalla; Milan G Chheda; Benito Campos; Alan Wang; Cameron Brennan; Keith L Ligon; Frank Furnari; Webster K Cavenee; Ronald A Depinho; Lynda Chin; William C Hahn
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

7.  Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.

Authors:  Sean A Grimm; Maryanne Marymont; James P Chandler; Kenji Muro; Steven B Newman; Robert M Levy; Borko Jovanovic; Katie McCarthy; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

Review 8.  Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.

Authors:  Amy K LeBlanc; Christina Mazcko; Diane E Brown; Jennifer W Koehler; Andrew D Miller; C Ryan Miller; R Timothy Bentley; Rebecca A Packer; Matthew Breen; C Elizabeth Boudreau; Jonathan M Levine; R Mark Simpson; Charles Halsey; William Kisseberth; John H Rossmeisl; Peter J Dickinson; Timothy M Fan; Kara Corps; Kenneth Aldape; Vinay Puduvalli; G Elizabeth Pluhar; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2016-05-14       Impact factor: 12.300

9.  Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.

Authors:  Young Dong Yoo; Dae-Hee Lee; Hyunjoo Cha-Molstad; Hyungsin Kim; Su Ran Mun; Changhoon Ji; Seong Hye Park; Ki Sa Sung; Seung Ah Choi; Joonsung Hwang; Deric M Park; Seung-Ki Kim; Kyung-Jae Park; Shin-Hyuk Kang; Sang Cheul Oh; Aaron Ciechanover; Yong J Lee; Bo Yeon Kim; Yong Tae Kwon
Journal:  EMBO Rep       Date:  2016-12-19       Impact factor: 8.807

10.  A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

Authors:  Priya Kumthekar; Sean Grimm; James Chandler; Minesh Mehta; Maryanne Marymont; Robert Levy; Kenji Muro; Irene Helenowski; Katie McCarthy; Leanne Fountas; Jeffrey Raizer
Journal:  J Neurooncol       Date:  2017-05-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.